Search results: (10000)
News Gliflozins Successfully Treat Type 2 Diabetes Mellitus and Heart Failure
The number of patients with type 2 diabetes mellitus (DM2) and heart failure is increasing worldwide, and the combination of both diseases significantly worsens the prognosis of patients. One of the main causes of increased mortality in these patients is macrovascular complications of DM2. The burden on the cardiovascular system is even greater with the concurrent occurrence of chronic heart failure.
News Impact of Lurasidone on Metabolic Functions Compared to Other Antipsychotics – Results of a Large Meta-Analysis
Antipsychotic therapy is associated with varying degrees of metabolic abnormalities in parameters of weight, lipid metabolism, and glucose metabolism. The presence of metabolic syndrome or isolated disorders of glucose and lipid metabolism further increases the risk of morbidity and mortality in patients with schizophrenia compared to the general population. Lurasidone is an antipsychotic indicated for the acute and maintenance treatment of schizophrenia. The advantage of this drug is its low risk of metabolic side effects, which has been confirmed in a recent large meta-analysis of clinical studies.
News Modern View on Schizophrenia Therapy Through the Lens of Lurasidone
At the psychiatric symposium titled 'Chance for a Better Quality of Life with a Schizophrenia Diagnosis', which took place on October 18, 2021, in Prague, Professor of Psychiatry and Molecular Biology Christoph U. Correll from the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell spoke. His lecture included insights on current approaches to schizophrenia therapy and key information on one of the newest antipsychotics - lurasidone.
News Lurasidone in the Treatment of Adolescent Schizophrenia: How Does It Compare with Other Atypical Antipsychotics?
A meta-analysis of 13 studies comparing lurasidone with other atypical antipsychotics in monotherapy for adolescent patients with schizophrenia evaluated the effectiveness of the treatment, the rate of weight gain, and the frequency of medication discontinuation for each modality.
News Improvement in social functioning of patients with schizophrenia during treatment with lurasidone
A beneficial impact on social functioning is an important outcome of schizophrenia treatment. A recently published Japanese study is the first to demonstrate the efficacy of lurasidone compared to placebo on the social functioning of patients with schizophrenia. The results are comparable to other atypical antipsychotics.
News Case Study of a Patient with NSCLC − with Voting
Presented by: MUDr. Leona Koubková,
Pneumology Clinic, 2nd Faculty of Medicine, Charles University and Motol University Hospital in Prague
News Postpartum Uterine Artery Pseudoaneurysm in a Woman with vWD – Case Study
Women with von Willebrand disease (vWD) have a significantly higher risk of postpartum hemorrhage. American experts from University Hospital in Augusta have published their experience with an unusual case of secondary postpartum hemorrhage in a young woman with type 1 vWD.
News Bone density in hemophiliacs − known and less-known risk factors
Osteopenia or osteoporosis are known comorbidities of hemophilia and concern many of these patients. What all contributes to their development?
News Hereditary Angioedema as a Clinical Picture of Excessive Activation of the Kinin Cascade – Case Report
Painful and potentially life-threatening swellings are characteristic of hereditary angioedema (HAE), a rare genetically determined disease. Dutch authors present in a recently published review the case report of a young woman with a life-threatening laryngeal swelling.
News Does the choice of therapy for primary hypertension in patients with COVID-19 affect the severity of the disease?
The effect of two commonly used antihypertensives was evaluated in a randomized clinical trial in patients with primary hypertension and COVID-19.
News Current Challenges in Diagnosing Progressive Fibrotic Interstitial Lung Diseases
A subset of patients with interstitial lung diseases exhibits a progressive fibrotic phenotype associated with a deterioration in quality of life and increased mortality. Early diagnosis and adequate therapy could improve their prognosis, but currently, there are numerous problems and challenges.
News Can Empagliflozin Also Act Against Gout?
Gliflozins, or sodium-glucose cotransporter 2 inhibitors (SGLT2i), are not only effective antidiabetic agents but also exhibit cardio - and renoprotective effects. It now appears that in type 2 diabetics, they may lower serum uric acid levels and help prevent the development of gout. This was suggested by a post hoc analysis of data from the EMPA-REG OUTCOME study in the case of empagliflozin.
News Position of the Aclidinium-Bromide/Formoterol-Fumarate Combination in COPD Treatment According to Current Recommendations
Dual bronchodilator therapy, which combines long-acting muscarinic antagonists (LAMA) and long-acting β-agonists (LABA), has become an integral part of the treatment for chronic obstructive pulmonary disease (COPD). Growing evidence of the efficacy and safety of the fixed combination of aclidinium-bromide/formoterol-fumarate demonstrates that this treatment meets patient needs and the current GOLD recommendations from 2019.
News Study TACTIC – Efficacy and Safety of Trifluridine/Tipiracil in Pre-treated mCRC Patients in Real-world Practice
In the pivotal phase III RECOURSE randomized placebo-controlled study, therapy with trifluridine/tipiracil (FTD/TPI) was associated with improved overall survival and progression-free survival in pre-treated metastatic colorectal cancer (mCRC) patients. The below-presented TACTIC study provides prospective data from German real-world practice.
News Prediction of Hypocalcemia Risk in Patients Treated with Denosumab and Active Form of Vitamin D
According to new work by Japanese authors, it appears that the risk factors for the development of hypocalcemia in patients treated with denosumab and calcitriol (the active form of vitamin D) are different from those when natural vitamin D is added to denosumab.
News Efficacy and Safety of Two Pharmacokinetically-Driven Prophylactic Regimens in People with Hemophilia A
Standard prophylaxis for bleeding in hemophilia A, based on the administration of coagulation factor VIII (FVIII), depends on the patient's weight, the severity of the coagulation factor deficiency, and the nature of bleeding episodes. The current trend, however, is an individualized approach in prophylaxis, which can improve clinical outcomes and optimize bleeding disorder therapy. A clinical study evaluated the efficacy and safety of two prophylactic regimens with different target trough levels of FVIII.
News Tailored Treatment. Who is Teriflunomide Suitable For?
The authors of the recently published study cited below not only focused on the safety and efficacy of teriflunomide in real-world clinical practice but also on the risk factors for its insufficient effectiveness. Who is teriflunomide most suitable for, and when should alternatives be considered?
News Adequate Compensation of a Hypertensive Patient According to Current ESC Guidelines – Case Study
A 65-year-old man, hypertensive, visits the general practitioner for a check-up. He reports recent shortness of breath during mild exertion (walking up stairs). Two months ago, he had acute sinusitis, for which he was prescribed antibiotics (penicillin V) by a specialist. He experiences hip pain and suffers from a runny nose in the spring (allergy?). He has been treated for hypertension for approximately 8 years.
News Cognitive changes in MS – what can teriflunomide do?
In Phase III clinical trials, teriflunomide demonstrated its ability to slow down brain tissue atrophy in patients with relapsing-remitting multiple sclerosis (RRMS). What impact did the treatment have on the cognitive state of these patients?
News Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A
Rurioctocog alfa pegol represents a modern modality for the treatment of hemophilia from the group of factors with an extended half-life. The authors of a systematic review and meta-analysis published last year assessed its efficacy and safety in patients previously treated for hemophilia A.
News Efficacy of Luspatercept in 1st Line Treatment of Anemia Due to Low-Risk Myelodysplastic Syndrome
A planned interim analysis of the COMMANDS study showed a greater benefit of the innovative treatment with luspatercept compared to the established treatment with epoetin alfa in patients with anemia due to low-risk myelodysplastic syndrome (MDS) and untreated with erythropoiesis-stimulating agents (ESA). The results were published in June 2023 in the journal Lancet.
News 6 Years Follow-Up of Patients with Breast Cancer in the APHINITY Study
The primary analysis of results from the APHINITY clinical trial supported the combined anti-HER2 treatment with trastuzumab and pertuzumab in combination with chemotherapy in patients with early HER2-positive breast cancer. At the end of last year, efficacy and safety results of this treatment after more than 6 years of follow-up were presented.
News Teriflunomide "under the microscope" or what it's like to live with MS in the North
The Teri-LIFE study examined teriflunomide very comprehensively. How does it manage to affect the quality of life of patients with multiple sclerosis (MS) according to data from real clinical practice in the Nordic countries? What is adherence to this therapy like? And what are its health-economic consequences? We briefly summarize the answers to these questions.
News Biochemotherapy of Aggressive Rectal Carcinoma – A Case Study from the Czech Republic
Colorectal cancer arises from a complex interplay of environmental and lifestyle factors complemented by hereditary factors. Nowadays, it represents not only a health concern but also a socioeconomic problem. It is the second most common malignant tumor in both sexes; fortunately, its incidence and mortality have been decreasing in recent years. Due to expanding and more accurately targeted treatment options and good patient care management, it is also possible to better manage more aggressive and previously difficult-to-treat forms of the disease, as demonstrated by the following case study from the Comprehensive Cancer Center of the University Hospital Hradec Králové.
News Current Options and Prospects for Effective Antiemetic Treatment in an Effort to Increase Adherence of Oncological Patients to Chemotherapy
Chemotherapy-induced nausea and vomiting (CINV) is strongly associated with treatment in the minds of many oncology patients, and its occurrence is rated as one of the most dreaded and stressful complications. For most patients, adherence to recommendations for antiemetic prophylaxis can successfully prevent the occurrence of CINV. A review article published last year by an international team of authors in the journal Future Oncology provides an overview of the current spectrum of options in CINV prophylaxis, focusing on the first combined preparation in this indication, containing the active substances netupitant and palonosetron.